Paul D. Levin is a registered patent agent in the Intellectual Property Practice Group of Pepper Hamilton LLP, resident in the Pittsburgh office.
Dr. Levin holds a Ph.D. in biophysics from the University of Virginia where his research focused on the probability distribution of spin-label states of the iron centers of myglobin solutions. While pursuing his doctorate, he developed expertise in a number of wet biochemistry techniques as well as a deep understanding of probability theory and statistical moment analysis. This research further extended his already significant background in biochemistry gained as an undergraduate at Dartmouth College, from which he graduated magna cum laude with high distinction in an honors major. His doctoral research has been published in Physics Review Letters and the Journal of Physical Chemistry.
In addition to his Ph.D., Dr. Levin also holds two masters degrees: an M.S.E.E., with specialization in digital signal processing, from the University of Pittsburgh School of Engineering and an M.S.L. from the University of Pittsburgh School of Law with a certificate in intellectual property law. As part of his law school education, he wrote a seminar paper on the Hatch-Waxman Act that was subsequently published in the Journal of the Patent and Trademark Office Society.
Prior to joining the firm, Dr. Levin was a principal biomedical researcher in the Corporate Innovations Group at Medrad, Inc. In this capacity, he worked in several capacities including project lead for groups investigating novel technologies for use in the medical device field, and work with regulatory professionals in areas related to clinical trials involving prototype medical devices. In addition, Dr. Levin developed scientific relationships with members of contract research organizations who he directed in studies involving stem cell research. On the patent side, he provided freedom-to-operate analyses and patent landscape analyses for a number of inventions. As a patent agent, he further helped prosecute a number of U.S. patent applications, and was the main point of contact between the Medrad IP Legal Group and Medrad’s patent associates in China and Japan.
